DECIDE - Decision-making within cell and differentiation entity theapies
Third-party funded project
Project title DECIDE - Decision-making within cell and differentiation entity theapies
Principal Investigator(s) Rolink, Antonius G.
Organisation / Research unit Departement Biomedizin / Developmental and Molecular Immunology (Rolink)
Project Website http://www.birmingham.ac.uk/decide
Project start 01.03.2013
Probable end 28.02.2017
Status Completed
Abstract

The DECIDE ITN brings together scientists who have made important advances in the fields of haematopoiesis and differentiation therapy and has both scientific and therapeutic targets. DECIDE aims to advance understanding of normal blood cell development and why primitive cells fail to differentiate in acute myeloid leukaemia (AML). We will use the information gained to develop ways of alleviating the differentiation block in AML and so deliver new agents, including novel vitamin D and retinoid analogues, for use in differentiation therapy. This type of therapy aims to respond to the urgent need to devise milder treatments, especially for older and frailer AML patients.

Financed by Commission of the European Union
   

MCSS v5.8 PRO. 0.978 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
17/07/2018